Host biomarkers of clinical relevance in tuberculosis: Review of gene and protein expression studies

Biomarkers

Volumn 17, Issue 1, 2012, Pages 1-8

  John, Serene H ^a   Kenneth, John ^a   Gandhe, Archana S ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

Active TB; Blood; Differential expression; Latent TB; Peripheral blood mononuclear cells (PBMCs)

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

DISEASE MARKER; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LATENT TUBERCULOSIS; MEDLINE; MICROARRAY ANALYSIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUBERCULOSIS; UPREGULATION;

BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; HUMANS; INFORMATION STORAGE AND RETRIEVAL; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; INTERLEUKIN-6; LATENT TUBERCULOSIS; LEUKOCYTES, MONONUCLEAR; PROTEOMICS; TUBERCULOSIS, PULMONARY;

EID: 84856457983     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.628048     Document Type: Review

References (66)

1. Aabye MG, Ravn P, PrayGod G, Jeremiah K, Mugomela A, Jepsen M, Faurholt D, Range N, Friis H, Changalucha J, Andersen AB. (2009). Te impact of HIVinfection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. PLoS ONE 4:e4220.
2. Agranof D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, Rayner CF, Krishna S.(2006). Identifcation of diagnostic markers for tuberculosis by proteomic fngerprinting of serum. Lancet 368: 1012-1021. (Pubitemid 44353670)
3. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, Benagiano M, D'Elios MM, Mantovani A, Del Prete G. (2005). IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring infammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 7:1-8. (Pubitemid 40431338)
4. Babu S, Bhat SQ, Kumar NP, Kumaraswami V, Nutman TB. (2010). Regulatory T cells modulate T17 responses in patients with positive tuberculin skin testresults. J Infect Dis 201:20-31.
5. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, Vanini V, Girardi E, Goletti D, D' Amelio R, Nisini R. (2010). Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect16:1282-1284.
6. BurlS, HillPC, Jefries DJ, HollandMJ, FoxA, LugosMD, AdegbolaRA, Rook GA, Zumla A, McAdam KP, Brookes RH. (2007). FOXP3 gene expression in a tuberculosis case contact study. Clin Exp Immunol 149:117-122. (Pubitemid 46897109)
7. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. (2009). Host markers in QuantiFERON supernatants diferentiate active TB fromlatentTB infection: preliminaryreport. BMC Pulm Med9:21.
8. Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q, Liu H, Zhou B. (2010). Reduced T17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T Cells. Am J Respir Crit Care Med 181:734-742.
9. Delgado JC, Tsai EY, Tim S, Baena A, Boussiotis VA, Reynes JM, Sath S, Grosjean P, Yunis EJ, Goldfeld AE. (2002). Antigen-specifc and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci USA 99:7576-7581. (Pubitemid 34568733)
10. Demissie A, Abebe M, Asefa A, Rook G, Fletcher H, Zumla A, Weldingh K, Brock I, Andersen P, Doherty TM; VACSEL Study Group. (2004). Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of T1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 172:6938-6943. (Pubitemid 38669133)
11. Deveci F, Akbulut HH, Turgut T, Muz MH. (2005). Changes in serum cytokine levels in active tuberculosis with treatment. Mediators Infamm 2005:256-262. (Pubitemid 41577415)
12. Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, Johnson MA, Rook GA, Zumla A. (2005). In vivo and in vitro studies ofanovel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med 172:501-508. (Pubitemid 41117397)
13. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G. (2009). Diferential cytokine secretion and early treatment response in patients with pulmonarytuberculosis. Clin Exp Immunol 156:69-77.
14. Djoba Siawaya JF, Chegou NN, van den Heuvel MM, Diacon AH, Beyers N van Helden P, Walzl G. (2009). Diferential cytokine/ chemokines and KL-6 profles in patients with diferent forms of tuberculosis. Cytokine 47:132-136.
15. Doherty TM, Wallis RS, Zumla A. (2009). Biomarkers ofdisease activity, cure, and relapse in tuberculosis. Clin Chest Med30:783-96, x.
16. Fletcher HA, Owiafe P, Jefries D, Hill P, Rook GA, Zumla A, DohertyTM, Brookes RH; VACSEL Study Group. (2004). Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology112:669-673. (Pubitemid 39061493)
17. Frahm M, Goswami N, Owzar K, Hecker E, Mosher A, Cadogan E, Ferrari G, Nahid P,Stout J. (2010). Multi-cytokine Profles After Tuberculosis Antigen Stimulation: A Search For New Biomarkers For Latent And Active Tuberculosis. Am J Respir Crit Care Med 181:A2261.
18. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. (2006). Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 173:803-810.
19. Handzel ZT, Barak V, Altman Y, Bibi H, Lidgi M, Iancovici-Kidon M, Yassky D, Raz M. (2007). Increased T1 and T2 type cytokine production in patients with active tuberculosis. Isr Med Assoc J 9:479-483. (Pubitemid 46979155)
20. Hasan Z, Clif JM, Dockrell HM, Jamil B, Irfan M, Ashraf M, Hussain R. (2009a). CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. PLoS ONE 4:e8459.
21. Hasan Z, Jamil B, Ashraf M, Islam M, Dojki M, Irfan M, Hussain R. (2009b). Diferential live Mycobacterium tuberculosis-, M. bovis BCG-, recombinant ESAT6-, and culture fltrateprotein 10-induced immunityintuberculosis. Clin Vaccine Immunol 16:991-998.
22. He XY, Xiao L, Chen HB, Hao J, Li J, Wang YJ, He K, Gao Y, Shi BY (2010). T regulatory cells and T1/T2 cytokines in peripheral blood from tuberculosis patients. Eur J Clin Microbiol Infect Dis 29:643-650.
23. Hussain R, Kaleem A, Shahid F, Dojki M, Jamil B, Mehmood H, Dawood G, Dockrell HM. (2002). Cytokine profles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population. J Immunol Methods 264:95-108. (Pubitemid 34615896)
24. Immanuel C, Swamy R, Kannapiran M, Vijayalakshmi S, Sundaram V Jagannath K, Paramasivan CN. (1997). Neopterin as a marker for cell-mediated immunity in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 1:175-180. (Pubitemid 127509676)
25. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, Ziegler A, Kaufmann SH. (2007). Candidate biomarkers for discrimination between infection and disease caused by Mycobacteriumtuberculosis.? J Mol Med 85:613-621. (Pubitemid 46876510)
26. Jacobsen M, Repsilber D, Kleinsteuber K, Gutschmidt A, Schommer-Leitner S, Black G, Walzl G, Kaufmann SH. (2010). Suppressor of cytokine signaling (SOCS)-3 is afected in T cells from TB patients. Clin Microbiol Infect: DOI: 10.1111/j.469-0691.2010.03326.x.
27. Kaido T. (2007). Characteristics and quality ofrandomized controlled trials in the treatment of hepatocellular carcinoma. Dig Dis Sci 52:1108-1113. (Pubitemid 46481276)
28. Kaido T, Uemoto S. (2008). Quality assessment of randomized controlled trials involving liver surgery. Hepatogastroenterology 55:1678-1680.
29. Kaufmann SH. (2010). Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med 267:337-353.
30. Kaufmann SH, McMichael AJ. (2005). Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11:S33-S44. (Pubitemid 40562302)
31. Lange C, Pai M, Drobniewski F, Migliori GB. (2009). Interferon-gamma release assays for the diagnosis of active tuberculosis: sensible or silly? Eur Respir J 33:1250-1253.
32. Lui G, Lee N, Cheung SW, Lam JS, Wong BC, Choi KW, Wong KT, Wong RY, Cockram CS, Hui DS, Chan RC. (2011). Interferon gamma release assay for diferentiating tuberculosis among pneumonia casesin acute healthcare setting. J Infect 62:440-447.
33. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G, Walzl G, Kaufmann SH. (2011). Human gene expression profles of susceptibility and resistance in tuberculosis. Genes Immun 12:15-22.
34. MatsuyamaW, Kubota R, Hashiguchi T, Momi H, Kawabata M, Nakagawa M, Arimura K, Osame M. (2002). Purifed protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro. Immunology 106:96-101. (Pubitemid 34437882)
35. Mattos AM, Almeida C, de S, Franken KL, Alves CC, Abramo C, de Souza MA, L'Hotellier M, Alves MJ, Ferreira AP, Oliveira SC, Ottenhof TH, Teixeira HC. (2010). Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol 22:775-782.
36. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). (2010). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection -United States, 2010.MMWR Recomm Rep 59:1-25.
37. Mistry R, Clif JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, Dockrell HM, Wallace DM, van Helden PD, Duncan K, Lukey PT. (2007). Gene-expression patterns in whole blood identify subjects at riskfor recurrent tuberculosis. J Infect Dis 195:357-365. (Pubitemid 46146113)
38. Nagabhushanam V, Solache A, Ting LM, Escaron CJ, Zhang JY, Ernst JD. (2003). Innate inhibition ofadaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 171:4750-4757. (Pubitemid 37310593)
39. Nemeth J, Winkler HM, Karlhofer F, Selenko-Gebauer N, Graninger W, Winkler S. (2010). T cells co-producing Mycobacterium tuberculosis-specifc type 1 cytokines for the diagnosis of latent tuberculosis. Eur Cytokine Netw 21:34-39.
40. Othieno C, Hirsch CS, Hamilton BD, Wilkinson K, Ellner JJ, Toossi Z. (1999). Interaction of Mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10. Infect Immun 67:5730-5735. (Pubitemid 29508092)
41. Parida SK, Kaufmann SH. (2010). Te quest for biomarkers in tuberculosis. Drug Discov Today 15:148-157.
42. Petrucci R, Abu Amer N, Gurgel RQ, Sherchand JB, Doria L, Lama C,Ravn P, Ruhwald M, Yassin M, Harper G, Cuevas LE. (2008). Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr Infect Dis J27:1073-1077.
43. Pokkali S, Das SD. (2009). Augmented chemokine levels and chemokinereceptorexpressiononimmunecellsduringpulmonary tuberculosis. Hum Immunol70:110-115.
44. Roberts T, Beyers N, Aguirre A, Walzl G. (2007). Immunosuppression during active tuberculosis is characterized by decreasedinterferon-gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels. J Infect Dis 195:870-878. (Pubitemid 46363933)
45. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. (2009). IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2:19.
46. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, Ravn P. (2007). CXCL10/IP-10 release is induced by incubation ofwhole blood from tuberculosis patients with ESAT-6, CFP10 andTB7.7. Microbes Infect 9:806-812. (Pubitemid 46901043)
47. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, Ravn P; TBNET. (2008). Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis oftuberculosis. Eur Respir J 32:1607-1615.
48. Sai Priya VH, Anuradha B, Latha Gaddam S, Hasnain SE, Murthy KJ, Valluri VL. (2009). In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis. Clin Vaccine Immunol 16:111-115.
49. Sargentini V, Mariotti S, Carrara S, Gagliardi MC, Teloni R, Goletti D,Nisini R. (2009). Cytometric detection of antigen-specifc IFN-gamma/IL-2 secreting cells in the diagnosis oftuberculosis. BMC Infect Dis9:99.
50. Seah GT, Scott GM, Rook GA. (2000). Type 2 cytokine gene activation and itsrelationship to extent ofdisease inpatientswith tuberculosis. J Infect Dis 181:385-389. (Pubitemid 30049076)
51. Stern JN, Keskin DB, Romero V, Zuniga J, Encinales L, Li C, Awad C, Yunis EJ. (2009). Molecular signatures distinguishing active from latent tuberculosis in peripheral blood mononuclear cells, after in vitro antigenic stimulation with purifed protein derivative of tuberculin (PPD) or Candida: a preliminary report. Immunol Res 45:1-12.
52. Su WL, Perng WC, Huang CH, Yang CY, Wu CP, Chang FY, Chen JH. (2010). Identifcation of cytokines in whole blood for diferential diagnosisoftuberculosisversuspneumonia. Clin Vaccine Immunol 17:771-777.
53. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. (2009). Pattern and diversityofcytokine production diferentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 39:723-729.
54. Sutherland JS, de Jong BC, Jefries DJ, Adetifa IM, Ota MO. (2010). Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS ONE 5:e12365.
55. Talreja J, Bhatnagar A, Jindal SK, Ganguly NK. (2003). Infuence of Mycobacterium tuberculosis on diferential activation of helper T-cells. Clin Exp Immunol131:292-298. (Pubitemid 36205142)
56. Tuong NT, Dunstan SJ, Chau TT, Torsson V, Simmons CP, Quyen NT, T waites GE, Ti Ngoc Lan N, Hibberd M, Teo YY, Seielstad M, Aderem A, Farrar J J, Hawn TR. (2008). Identifcation of tuberculosis susceptibility genes with human macrophage gene expression profles. PLoS Pathog 4:e1000229.
57. Turgut T, Akbulut H, Deveci F, Kacar C, Muz MH. (2006). Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis. Tohoku J Exp Med 209:321-328. (Pubitemid 44144901)
58. Verbon A, Jufermans N, Van Deventer SJ, Speelman P, Van Deutekom H Van Der Poll T. (1999). Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol115:110-113. (Pubitemid 29030371)
59. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. (2010). Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet375:1920-1937.
60. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. (2011). Immunological biomarkers of tuberculosis. Nat Rev Immunol 11:343-354.
61. Wassie L, Demissie A, Asefa A, Abebe M, Yamuah L, Tilahun H, Petros B, Rook G, Zumla A, Andersen P, Doherty TM; VACSEL Study Group. (2008). Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time. PLoS ONE 3:e1522.
62. Whittaker E, Gordon A, Kampmann B. (2008). Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma PLoS ONE 3:e3901.
63. WHO. (2009). Global tuberculosis control. A short update to the 2009 report, Geneva.
64. Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, KrenskyAM, Clayberger C. (2007). Messenger RNA expression ofIL-8, FOXP3, and IL-12beta diferentiates latent tuberculosis infection from disease. J Immunol 178:3688-3694. (Pubitemid 46417636)
65. Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, Clayberger C. (2008). IL-9 is associated with an impaired T1 immune response in patients with tuberculosis. Clin Immunol 126:202-210.
66. Zhang Y Broser M, Rom WN. (1994). Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. Proc Natl Acad Sci USA 91:2225-2229. (Pubitemid 24092076)